American College of Clinical Pharmacy
      Search      Cart
         

Pediatric PRN Focus Session -- To Inhale or Not to Inhale: Insights into Aerosolized Medications in the Pediatric Population

Sunday, October 08, 2017 from 4:00 PM to 5:30 PM MST at Phoenix Convention Center North Building Street Level: Meeting Room 124

Available for 1.50 hours of CPE credit
Activity Number: 0217-0000-17-147-L01-P
Activity Type: An Application-Based Activity


Speakers
  • Kalen B. Manasco, Pharm.D., BCPS, AE-CModerator: Kalen B. Manasco, Pharm.D., BCPS, AE-C
    Clinical Professor and Division Head, Department of Pharmacotherapy and Translational Research, University of Florida College of Pharmacy, Gainesville, Florida
      View Biography

Introduction to Aerosolized Medications in Pediatric Patients and Evaluation of Aerosolized Antimicrobials
4:00 PM

Speakers
  • Hanna  Phan, Pharm.D., FCCPSpeaker: Hanna Phan, Pharm.D., FCCP
    Associate Professor, Department of Pharmacy Practice and Science and Pediatrics, Colleges of Pharmacy and Medicine; Associate Research Scientist, Asthma and Airway Disease Research Center - University of Arizona, Tucson, Arizona
      View Biography


Learning Objectives
1. Describe the age-specific processes and pharmacokinetic properties to consider when evaluating a medication for aerosolized, intranasal, and inhaled routes of administration.
2. Analyze current literature evaluating aerosolized antimicrobials in pediatric patients, including those with cystic fibrosis.
Evaluation of Aerosolized Medications in Pediatric Critical Care Patients
4:25 PM

Speakers
  • Jennifer L. Morris, Pharm.D., BCPSSpeaker: Jennifer L. Morris, Pharm.D., BCPS
    Clinical Pharmacy Specialist, Extracorporeal Therapies and Renal, Texas Children's Hospital, Houston, Texas
      View Biography


Learning Objectives
1. Evaluate the safety and efficacy of aerosolized medications for pain and palliative care.
2. Evaluate the safety and efficacy of aerosolized medications for pulmonary hypertension.
3. Evaluate the safety and efficacy of aerosolized medications for plastic bronchitis.
Pro-Con Debate on the Use of Dornase Alfa for Non-Cystic Fibrosis Indications
4:50 PM

Speakers
  • Speaker: Hanna Phan, Pharm.D., FCCP
    Associate Professor, Department of Pharmacy Practice and Science and Pediatrics, Colleges of Pharmacy and Medicine; Associate Research Scientist, Asthma and Airway Disease Research Center - University of Arizona, Tucson, Arizona
      View Biography


Learning Objectives
1. Debate current literature regarding the use of dornase alfa for non-cystic fibrosis indications.
2. Develop a recommendation regarding the appropriateness of utilizing dornase alfa for non-cystic fibrosis indications.